Jefferies Confident In $400M+ U.S. Cinryze Sales for ViroPharma (VPHM)
Tweet
Share
E-mailGet Alerts VPHM Hot Sheet
Price: $49.96 --0%
Rating Summary:
5 Buy, 9 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
5 Buy, 9 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Jefferies reiterated their Buy and $24 price target on ViroPharma (NASDAQ: VPHM) following a presentation at the Jefferies 2011 Global Healthcare Conference.
The firm said, "At our healthcare conference, VPHM provided several positive updates on U.S. Cinryze demand, European regulatory review, European pricing, supply capacity, and the subcutaneous formulations of Cinryze. We remain confident in $400m+ U.S. Cinryze."
For more ratings news on ViroPharma click here and for the rating history of ViroPharma click here.
Shares of ViroPharma closed at $17.76 yesterday.
The firm said, "At our healthcare conference, VPHM provided several positive updates on U.S. Cinryze demand, European regulatory review, European pricing, supply capacity, and the subcutaneous formulations of Cinryze. We remain confident in $400m+ U.S. Cinryze."
For more ratings news on ViroPharma click here and for the rating history of ViroPharma click here.
Shares of ViroPharma closed at $17.76 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cummins (CMI) PT Lowered to $675 at Jefferies
- Rockwell Automation (ROK) PT Lowered to $490 at DA Davidson
- Beike (BEKE) PT Raised to $23 at Morgan Stanley
Create E-mail Alert Related Categories
Analyst Comments, FDARelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
